Lpath's kidney cancer drug fails mid-stage trial

March 24, 2015 8:36 PM

16 0

(Reuters) - Drug developer Lpath Inc said its experimental drug to treat renal cell carcinoma, the most common form of kidney cancer, failed to meet its main goal in a mid-stage trial.

Patients taking the drug, Asonep, did not show significant survival rates without the disease worsening.

Also read: Intel chief Brian Krzanich resigns over relationship

Read more

To category page